Research Article

Topical Antinociceptive Effect of *Vanillosmopsis arborea* Baker on Acute Corneal Pain in Mice

Laura Hévila Inocêncio Leite, 1 Gerlância de Oliveira Leite, 1 Thales Silva Coutinho, 1 Severino Denício Gonçalves de Sousa, 1 Renata Souza Sampaio, 1 José Galberto Martins da Costa, 1 Irwin Rose Alencar de Menezes, 1 and Adriana Rolim Campos 2

1 Programa de Pós-Graduação em Bioprospecção Molecular, Universidade Regional do Cariri, 63105-000 Crato, CE, Brazil
2 Universidade de Fortaleza, Avenida Washington Soares 1321, 60811-905 Fortaleza, CE, Brazil

Correspondence should be addressed to Adriana Rolim Campos; adrirolim@unifor.br

Received 25 October 2013; Revised 7 December 2013; Accepted 19 December 2013; Published 10 February 2014

Academic Editor: Olumayokun A. Olajide

Copyright © 2014 Laura Hévila Inocêncio Leite et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study aimed to assess the possible topical antinociceptive activity of *Vanillosmopsis arborea* Baker essential oil (EOVA) and to clarify the underlying mechanism, using the acute model of chemical (eye wiping) nociception in mice. EOVA (25 to 200 mg/kg; p.o. and topical) evidenced significant antinociception against chemogenic pain in the test model of formalin-induced neuroinflammatory pain. Local application of 5 M NaCl solution on the corneal surface of the eye produced a significant nociceptive behavior, characterized by eye wiping. The number of eye wipes was counted during the first 30 s. EOVA (25, 50, 100, and 200 mg/kg; p.o. and topical) significantly decreased the number of eye wipes. Naloxone, yohimbine, L-NAME, theophylline, glibenclamide, and ruthenium red had no effect on the antinociceptive effect of EOVA. However, ondansetron, p-chlorophenylalanine methyl ester (PCPA), capsazepine, prazosin, and atropine prevented the antinociception induced by EOVA. These results indicate the topical antinociceptive effect of EOVA and showed that 5-HT, α1, TRPV1, and central muscarinic receptors might be involved in the antinociceptive effect of EOVA in the acute corneal model of pain in mice.

1. Introduction

The small size of the cornea and the extensive branching of the peripheral axons of corneal neurons make this structure the most densely innervated tissue of the body [1]. The majority of corneal sensory fibers are polymodal nociceptors, which are activated by noxious mechanical, thermal, and chemical stimuli [2].

Safe, long-lasting pain relief following corneal abrasions, corneal ulcers or ophthalmic surgery is difficult to achieve with current analgesics. The use of topical NSAIDs and acetaminophen is constrained by their gradual onset and limited efficacy, and the adverse side effects of systemic opioids are well known [3].

*Vanillosmopsis arborea* Baker is native to the Araripe National Forest, in the Northeast of Brazil in the state of Ceará. There are few studies concerning the traditional use of this plant. However, biological and pharmacological studies have shown that its essential oil presents antimicrobial, antiinflammatory and gastroprotective activities [4].

Topically applied *Vanillosmopsis arborea* essential oil produced antinociception in acetic acid, cyclophosphamide, mustard oil, capsaicin or formalin-induced visceral pain [5]. The essential oil also suppressed the ear edema induced by Croton oil and phenol but no that one induced by histamine or capsaicin [6].

Ocular pain has not been adequately controlled in many patients and there is a lack of studies that examine the effect of *Vanillosmopsis arborea* on the perception of corneal pain. Therefore, the present study was designed to investigate the effects of acute topical administration of *Vanillosmopsis arborea* on acute corneal pain that was induced by hypertonic saline applied locally on the corneal surface in mice.
Table 1: Pharmacologic agents used for test in order to verify the possible action mechanism of EOVA antinociceptive effect.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Target</th>
<th>Dose (mg/kg)</th>
<th>Administration route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naloxone</td>
<td>Opioid receptors</td>
<td>2 (11)</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>Prazosin</td>
<td>$\alpha_1$-receptors</td>
<td>0.15 (12)</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>Yohimbine</td>
<td>$\alpha_2$-receptors</td>
<td>2 (11)</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>Theophylline</td>
<td>Adenosine receptors</td>
<td>5 (13)</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>L-NAME</td>
<td>NO synthesis</td>
<td>2 (11)</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>5-HT$_3$ receptors</td>
<td>0.5 (14)</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>Atropine</td>
<td>Muscarinic receptors</td>
<td>0.1 (15)</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>Glibenclamide</td>
<td>$K_{ATP}^+$ channels</td>
<td>2 (16)</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>Ruthenium red</td>
<td>TRPV$_1$ receptors</td>
<td>5 (13)</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>(noncompetitive antagonist)</td>
<td>3 (11, 17, 18) Subcutaneous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capsazepine</td>
<td>(competitive antagonist)</td>
<td>5 (16)</td>
<td>Intraperitoneal</td>
</tr>
</tbody>
</table>

2. Material and Methods

2.1. Essential Oil. The essential oil from *Vanillosmopsis arborea* Baker bark (EOVA) was obtained from the Natural Products Research Laboratory of Regional University of Cariri. The composition (w/w) of EOVA revealed the presence of $\alpha$-bisabolol to the extent of 70%. Other identified compounds were $\alpha$-cadinol (8.4%), elemicin (6.21%), $\beta$-bisabolene (4.46%), $\delta$-guaiane (2.31%), $\beta$-cubebene (1.76%), and estragole (1.08%).

2.2. Animals. Male Swiss albino mice (20–25 g) obtained from the Central Animal House of Regional University of Cariri were used. They were housed in environmentally controlled conditions (22°C, 12 h light-dark cycle), with free access to standard pellet diet (Purina, São Paulo, Brazil) and water. Animals were kept in cages with raised floors to prevent coprophagy. The experimental protocols were in accordance with the ethical guidelines of National Institute of Health, Bethesda, USA.

2.3. Formalin-Induced Paw Licking. The formalin-induced nociception was performed as described previously by Hunskar and Hole [7]. Groups of mice ($n = 8$) were treated with vehicle (10 mL/kg, p.o.), EOVA (25, 50, 100, or 200 mg/kg p.o. or topical), or morphine (75 mg/kg, s.c.) 30 or 60 min before the administration of 20 $\mu$L of 1% formalin (in 0.9% saline) into the plantar surface of the right hind paw. The duration of paw licking (s) as an index of painful response was determined at 0–5 min (early phase, neurogenic) and 20–25 min (late phase, inflammatory) after formalin injection.

2.4. Eye Wiping Test. Corneal nociception was induced by a local application of hypertonic saline to the corneal surface [8, 9]. One drop (40 $\mu$L) of 5 M NaCl solution was applied locally on the corneal surface of mice using a fine dropper [10]. The number of eye wipes performed with the ipsilateral forepaw was counted for a period of 30 s. Topical (20 $\mu$L/eye) or orally (10 mL/kg) EOVA (25, 50, 100 or 200 mg/kg; $n = 8$/group) or vehicle were given 1 h before the noxious agent. Morphine 7 mg/kg (s.c.; $n = 8$) was used as positive control. A normal control group ($n = 8$) received one drop of 0.15 M NaCl (0.9%).

In order to verify the possible involvement of opioid, noradrenergic, nitrergic, 5-HT$_3$, muscarinic, $K_{ATP}^+$ adenosinergic, and TRPV$_1$ systems in the effect of EOVA, the animals ($n = 8$/group) were treated with the respective antagonist (Table 1), 30 min before the topical administration of EOVA (50 mg/kg). The doses of antagonists were chosen based on previous studies.

To assess the possible contribution of endogenous serotonin, animals ($n = 8$/group) were pretreated with $\rho$-chlorophenylalanine methyl ester (PCPA, 100 mg/kg, i.p., an inhibitor of serotonin synthesis) or with vehicle, once a day for 4 consecutive days. Then, 24 hours after the last PCPA or vehicle injection, animals received EOVA (50 mg/kg) and 1 h later they were tested in the eye wiping test.

2.5. Statistical Analysis. All data are presented as mean ± s.e.m. The data were evaluated by one-way analysis of variance with Student-Newman-Keuls post hoc test using the GraphPad Prism 4.0 statistical program. The level of significance was set at $P < 0.05$.

3. Results and Discussion

In formalin test, pretreatment with EOVA (oral and topical) caused significant diminishments of both first phase (neurogenic) and second phase (inflammatory) nociception responses (Tables 2(a) and 2(b)). Morphine (5 mg/kg), the reference standard, also significantly suppressed the formalin-response at both phases.

Topically administered EOVA (25, 50, 100, or 200 mg/kg) respectively ($P < 0.001$, $P < 0.01$, $P < 0.01$, and $P < 0.0001$, resp.) decreased the number of eye wipes induced by the local application of 5 M NaCl solution on the corneal surface (Table 3(a)). Oral treatment with EOVA also reduced the number of eye wipes (Table 3(b)).
EOVA was evaluated for topical antinociceptive activity in mice using experimental models of chemogenic nociception. EOVA (oral and topical) was effective in attenuating acute neurogenic and tonic inflammatory phases of the formalin response. The essential oil, given topically, elicited a dose-unrelated antinociceptive effect on the paw-licking response, just as observed in the eye wiping test.

The local application of a 5 M NaCl solution to the corneal surface produced corneal nociception. Previous work has shown that the application of hypertonic saline to the tongue and cornea transiently activates nociceptive neurons with wide dynamic range property in the trigeminal subnucleus caudalis [11]. Moreover, infusion of hypertonic saline into the masseter muscle produces hind paw shaking in addition to corneal nociception induced by a local application of a 5 M NaCl solution in mice. Previous study showed the local antiinflammatory effect of EOVA, since the essential oil from V. arborea bark is topically active [10]. It was observed that EOVA effect can be related to release of leukotrienes, decrease the production of inflammatory eicosanoids and influence on the production of AA metabolites [6]. This antinociceptive effect may be related to the high α-bisabolol content in EOVA, since that α-bisabolol possess visceral antinociceptive activity [20] and it is able to reduce the neuronal excitability in a concentration-dependent manner [21].

In the present study, we attempted to characterize further some of the mechanisms through which EOVA exerts its antinociceptive action in chemical model of corneal pain in mice.

The antinociceptive effect induced by the EOVA (50 mg/kg) was significantly inhibited by ondansetron, PCPA, prazosin, atropine, and capsazepine (Tables 4, 5, 6, 7, and 8). On the other hand, the administration of glibenclamide, naloxone, rutenium red, yohimbine, LNAME or theophylline did not prevent the EOVA-induced antinociception (Tables 7, 9, 10, 11, 12, and 13).
Serotonergic neurons also play a crucial role in the control of pain [22] and the diversity of subtype receptors for serotonin makes this system able to exert either facilitatory or inhibitory function [23]. Spinal 5-HT\textsubscript{3} receptors have been shown to mediate antinociception, possibly via GABA release [24, 25]. Concerning the mechanism through which EOVA exerts its antinociceptive action, the present study shows that the 5-HT\textsubscript{3} receptor is likely involved. This conclusion derives from the fact that pretreatment of animals with the 5-HT\textsubscript{3} antagonist, ondansetron, reversed the antinociception caused by EOVA.

In addition, the treatment of mice with tryptophan hydroxylase inhibitor (PCPA) at a dose known to decrease the cortical content of serotonin and to significantly reverse morphine antinociception [26, 27] attenuated the effect of EOVA, indicating the involvement of 5-HT in the antinociceptive effect of EOVA.

In the present study, the involvement of \(\alpha_1\)-receptors in the antinociceptive action of EOVA is suggested by the results showing that pretreatment of animals with prazosin (an \(\alpha_1\)-receptor antagonist) significantly blocked the antinociception caused by EOVA. Prazosin, a former selective \(\alpha_1\)-receptor antagonist, has high affinity for \(\alpha_2\)-receptors [28]. It has been suggested that the effects of prazosin against spinal \(\alpha\) agonists appear through \(\alpha_2\)-receptors, although yohimbine interacts with \(\alpha_{2A}\)-receptor site as well as \(\alpha_{2B}\)-receptor site [29].

The roles of acetylcholine, cholinergic agonists, and cholinesterase inhibitors, collectively termed cholinomimetics, have been established in the modulation of pain and analgesia [30]. Here we show that the pretreatment of animals with atropine prevented the antinociceptive effect induced by EOVA. This result indicates that the muscarinic receptors are involved in EOVA-induced antinociceptive effect. It is already well established that the analgesic effect of systemic morphine is mediated by a descending cholinergic pathway [31] as well as spinal endogenous acetylcholine acting through muscarinic receptors [32–35].
Table 11: Effect of pretreatment with yohimbine on the EOVA-induced corneal antinociception in mice.

<table>
<thead>
<tr>
<th>Group</th>
<th>Dose (mg/kg)</th>
<th>Number of eye wipes (30 s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>—</td>
<td>17.00 ± 0.85</td>
</tr>
<tr>
<td>EOVA 50</td>
<td>10.33 ± 0.55**</td>
<td></td>
</tr>
<tr>
<td>L-NAME 10</td>
<td>7.33 ± 2.06***</td>
<td></td>
</tr>
<tr>
<td>+EOVA 50</td>
<td>9.16 ± 0.60***</td>
<td></td>
</tr>
</tbody>
</table>

Data are expressed as mean ± s.e.m. **P < 0.01 and ***P < 0.001 compared to control group. ANOVA followed by Student-Newman-Keuls test.

Table 12: Effect of pretreatment with L-NAME on the EOVA-induced corneal antinociception in mice.

<table>
<thead>
<tr>
<th>Group</th>
<th>Dose (mg/kg)</th>
<th>Number of eye wipes (30 s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>—</td>
<td>19.00 ± 0.57</td>
</tr>
<tr>
<td>EOVA 50</td>
<td>11.50 ± 0.67****</td>
<td></td>
</tr>
<tr>
<td>L-NAME 10</td>
<td>17.50 ± 0.84</td>
<td></td>
</tr>
<tr>
<td>+EOVA 50</td>
<td>12.83 ± 0.65****</td>
<td></td>
</tr>
</tbody>
</table>

Data are expressed as mean ± s.e.m. ****P < 0.001 compared to control group. ANOVA followed by Student-Newman-Keuls test.

Table 13: Effect of pretreatment with theophylline on the EOVA-induced corneal antinociception in mice.

<table>
<thead>
<tr>
<th>Group</th>
<th>Dose (mg/kg)</th>
<th>Number of eye wipes (30 s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>—</td>
<td>17.00 ± 0.85</td>
</tr>
<tr>
<td>EOVA 50</td>
<td>10.33 ± 0.55**</td>
<td></td>
</tr>
<tr>
<td>Theophylline</td>
<td>7.33 ± 2.06***</td>
<td></td>
</tr>
<tr>
<td>+EOVA 50</td>
<td>9.16 ± 0.60***</td>
<td></td>
</tr>
</tbody>
</table>

Data are expressed as mean ± s.e.m. ***P < 0.001 compared to control group. ANOVA followed by Student-Newman-Keuls test.

Ruthenium red (a noncompetitive TRPV1 antagonist) did not affect the antinociceptive effect of EOVA. However, capsazepine (a competitive TRPV1 channel antagonist) inhibited this response, indicating that EOVA interacts directly with TRPV1 receptors may contribute to this antinociception.

In summary, we have demonstrated that topical EOVA reduces the nociceptive behavior in models of formalin-induced paw licking and eye wiping in mice. In the corneal pain model, the observed antinociception is possibly mediated by 5-HT, α1, muscarinic, and TRPV1 receptors.

Conflict of Interests

There is no conflict of interests.

Acknowledgments

This research was supported by the grants and fellowships from CNPq, CAPES, and FUNCAP, Brazil.

References


Submit your manuscripts at http://www.hindawi.com